#immunotherapy

A third of patients treated with Opdivo plus Yervoy experienced complete or partial tumor remission.

Tecentriq plus Avastin improved improved overall survival and patient experiences during treatment.

Opdivo plus Yervoy led to higher response rates and longer survival than Opdivo alone.

Immunotherapy did not improve overall survival but led to fewer side effects and better quality of life.

Phase III study misses statistical threshold, but the immunotherapy appears to show some benefit.

Keytruda showed modest benefits for people with hepatocellular carcinoma, and combining Opdivo with Yervoy improved outcomes.

Seventy percent of liver cancer patients had either a partial response or stable disease.

A third of patients taking neoadjuvant Opdivo had complete responses in an early analysis.

Half of people with worse liver function responded well to immunotherapy.

A second immunotherapy option is now available for hepatocellular carcinoma.

Engineered T cells prevent recurrence over five years.

Immunotherapy had a low response rate, but most responders continue to do well.

The median survival exceeded 15 months for patients previously treated with the only approved first-line therapy.

Opdivo will be used to treat hepatocellular carcinoma, which can be caused by hepatitis B or C.